Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COLUMN
The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
To read the full story
COLUMN
- The Patient North Star: How Gilead Japan Redefined Innovation
April 8, 2026
- Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
March 27, 2026
- The Strategic MSL: Beyond Data Delivery, It’s About Impact
February 19, 2026
- AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential
January 27, 2026
- AI: Your New HR BFF (Not Your Replacement!)
December 24, 2025
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…